|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Neuropharmacology Group, Department of Neuroscience and Pharmacology, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark (C.J.L., U.G.); Psychobiology (R.I.D., J.L.K.) and Medicinal Chemistry Sections (M.-F.Z., J.C., P.G., A.H.N.), Medications Discovery Research Branch, Intramural Research Program, Department of Health and Human Services, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland; and Institute for Pharmacology, Center for Biomolecular Medicine and Pharmacology, Medical University Vienna, Vienna, Austria (K.G., H.H.S.)
Cocaine exerts its stimulatory effect by inhibiting the dopamine transporter (DAT). However, novel benztropine- and rimcazole-based inhibitors show reduced stimulant effects compared with cocaine, despite higher affinity and selectivity for DAT. To investigate possible mechanisms, we compared the subjective effects of different inhibitors with their molecular mode of interaction at the DAT. We determined how different inhibitors affected accessibility of the sulfhydryl-reactive reagent [2-(trimethylammonium)ethyl]-methanethiosulfonate to an inserted cysteine (I159C), which is accessible when the extracellular transporter gate is open but inaccessible when it is closed. The data indicated that cocaine analogs bind an open conformation, whereas benztropine and rimcazole analogs bind a closed conformation. Next, we investigated the changes in inhibition potency of [3H]dopamine uptake of the compounds at a mutant DAT (Y335A) characterized by a global change in the conformational equilibrium. We observed a close relationship between the decrease in potencies of inhibitors at this mutant and cocaine-like responding in rats trained to discriminate cocaine from saline injections. Our data suggest that chemically different DAT inhibitors stabilize distinct transporter conformations and that this in turn affects the cocaine-like subjective effects of these compounds in vivo.
Address correspondence to: Dr. Claus J. Loland, Molecular Neuropharmacology Group, Department of Neuroscience and Pharmacology, Faculty of Health Sciences, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark. E-mail: claus{at}neuropharm.ku.dk
Related articles in MolPharm:
This article has been cited by other articles:
![]() |
K. L. Nicholson, R. L. Balster, K. Golembiowska, M. Kowalska, J. P. Tizzano, P. Skolnick, and A. S. Basile Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine J. Pharmacol. Exp. Ther., July 1, 2009; 330(1): 236 - 248. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hiranita, P. L. Soto, A. H. Newman, and J. L. Katz Assessment of Reinforcing Effects of Benztropine Analogs and Their Effects on Cocaine Self-Administration in Rats: Comparisons with Monoamine Uptake Inhibitors J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 677 - 686. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. K. Henry and R. D. Blakely Distinctions between Dopamine Transporter Antagonists Could be Just around the Bend Mol. Pharmacol., March 1, 2008; 73(3): 616 - 618. [Abstract] [Full Text] [PDF] |
||||